Piper Sandler initiated coverage on NewAmsterdam Pharma with a new price target
$NAMS
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler initiated coverage of NewAmsterdam Pharma with a rating of Overweight and set a new price target of $37.00